1. Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 patients from the SOS AF project (Stroke prevention Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014; 35(8): 508-16.
2. He Boriani G, Glotzer TV, Santini M, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-53.
3. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-72.
4. Patel MR, Mahaffey KW, Garg J. et al. ROCKET AF Investigators. Collaborators (1236). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 2011; 365: 883-91.
5. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92.
6. Ezekowitz MD, Connolly S, Parekh A. Rationale and design of RE-LY®: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009; 157(5): 805-10.
7. National Heart, Lung, and Blood Institute. Types of Strokes. Available at: http://www.nhlbi. nih.gov/health/health-topics/topics/stroke/types.html. Accessed 21 November 2013.
8. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleedingin patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010; 138 (5): 1093.
9. Boriani G, Diemberger I, Biffi M, et al. Balancing the risk of hemorrhage vs thromboembolism in patients with atrial fibrillation: how to navigate between scylla and charybdis? Chest. 2010; 138 (5): 1032-3.
10. Lee JH, Park KY, Shin JH, et al. Symptomatic hemorrhagic transformation and its predictors in acute ischemic stroke with atrial fibrillation. Eur Neurol 2010; 64: 193-200.
11. Tan S, Wang D, Liu M, et al. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol 2014; 261: 905-12.
12. Nogueira RG, Gupta R, Jovin TG, et al. Predictors and clinical relevance of hemorrhagic transformation after endovascular therapy for anterior circulation large vessel occlusion strokes: a multicenter retrospective analysis of 1122 patients. J Neurointerv Surg 2014.
13. Ethem MA, Demet FB, Atalar Е, et al. Ischemic Stroke Phenotype in Patients With Nonsustained Atrial Fibrillation STROKEAHA.114.006396 Published online before print January 29, 2015, doi: 10.1161/STROKEAHA.114.006396.
14. Reliability and Limitations of Automated Arrhythmia Detection in Telemetric Monitoring After Stroke Natalia Kurka, Tobias Bobinger, Bernd Kallmünzer, Julia Koehn, Peter D. Schellinger, Stefan Schwab, and Martin Köhrmann Stroke. 2015; 46: 560-3, published online before print December 232014. doi:10.1161/STROKEAHA.114.007892.
15. Tu HT, Campbell BC, Christensen S, et al Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation. Int J Stroke 2013.
16. Alekseev OV. Microcirculatory homeostasis. Homeostasis (Ed. P.D. Gorizontova). M.: Meditsina, 1981; 419-60. Russian (Алексеев О.В. Микроциркуляторный гомеостаз. В кн: Гомеостаз. Под ред. П.Д. Горизонтова. М.: Медицина, 1981; 419-60).
17. Dementeva II, Charnaya MA, Morozov YuA. The hemostatic system during operations on the heart and great vessels. Disorders, prevention, correction: a guide for physicians. Seriya “Biblioteka vracha-spetsialista”. 2009. Russian (Дементьева И. И., Чарная М.А., Морозов Ю.А. Система гемостаза при операциях на сердце и магистральных сосудах. Нарушения, профилактика, коррекция: руководство для врачей. (Сер “Библиотека врача-специалиста”). 2009).
18. Ames A, Wright RL, Kowada M, et al. Cerebral ischemia. II. The no-reflow phenomenon. Am J Pathol 1968; 52: 437-53.
19. Paciaroni M, Agnelli G, Micheli S, et al. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. 2007; 38: 423-30.
20. Pfeilschifter W, Spitzer D, Czech-Zechmeister B, et al. Increased Risk of Hemorrhagic Transformation in Ischemic Stroke Occurring During Warfarin Anticoagulation An Experimental Study in Mice Stroke. 2011; 42: 1116-21.
21. Gliem M, Hermsen D, van Rooijen N, et al. Secondary Intracerebral Hemorrhage Due to Early Initiation of Oral Anticoagulation After Ischemic Stroke An Experimental Study in Mice Stroke. 2012; 43: 3352-57.
22. Lopes RD, Alexander JH, Al-Khatib SM, et al. ARISTOTLE Investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010; 159: 331-9.
23. Granger CB, Alexander JH, McMurray, et al. ARISTOTLE Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-92. 24. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33: 2821-30.